(Q44210437)

30 November 2017

title

Patients treated with vigabatrin exhibit central visual function loss (English)

1 reference

30 November 2017

Emma J Roff Hilton

1

1 reference

30 November 2017

Robert P Cubbidge

2

1 reference

30 November 2017

Sarah L Hosking

3

1 reference

30 November 2017

Tim Betts

4

1 reference

30 November 2017

Ian F Comaish

5

1 reference

30 November 2017

publication date

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

43

1 reference

30 November 2017

issue

11

1 reference

30 November 2017

page(s)

1351-1359

1 reference

Severe persistent visual field constriction associated with vigabatrin

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Visual function loss from vigabatrin: effect of stopping the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Vigabatrin-associated visual field defects in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Analysis of visual dysfunctions in HIV-positive patients without retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Normal variability of static perimetric threshold values across the central visual field

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Survey of the clinical use of glare and contrast sensitivity testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Contrast sensitivity and glare disability after radial keratotomy and photorefractive keratectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

Chronic human glaucoma causing selectively greater loss of large optic nerve fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2002.00502.X

10.1046/J.1528-1157.2002.00502.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference